個案總覽

Explores the origins and workings of the World Trade Organization (WTO), focusing particular attention on the special challenges of trade liberalization at the dawn of the 21st century.

Summarizes five major trade disputes before the World Trade Organization (WTO): (1) the Brazil-Canada aircraft dispute, (2) the European Union/United States foreign sales corporation dispute, (3) the Asian/United States shrimp and sea turtle dispute, (4) the United States/European Union beef hormones dispute, and (5) the U.S. steel tariff dispute.

Describes how major pharmaceutical firms changed their strategy and pricing policies in the years 2000 to 2002 to respond to the growing AIDS epidemic in Africa.

In the final years of the 20th century, the world was hit by a plague of epidemic proportions--AIDS, a life-threatening disease that remained stubbornly immune to any cure or vaccine. In the developed nations of the West, AIDS was slowly brought under control through a combination of education, prevention, and cutting-edge medicines. But in the developing world, where health care expenditures were often paltry, AIDS continued to rampage. By the year 2000, 25 million people in Africa alone were infected with the disease. Millions had already died. Nearly all of the medicines that treated AIDS had been developed--at great expense--by the major western pharmaceutical firms. These medicines were expensive to produce and often difficult to administer. They demanded levels of income and structures of distribution that often were sorely lacking in the developing world. Increasingly, activist groups were demanding that the pharmaceutical companies respond to the AIDS epidemic with drastic measures, giving their drugs away for free or abandoning the patent rights that had long protected their intellectual property. The pharmaceutical firms needed to respond to their critics. The question was, how?